Permanent expression of human CD59 and/or decay-accelerating factor by rat endothelial cells confers protection from human complement-mediated lysis.
Charreau
B
B
Institut National de la Santé et de la Recherche Médicale (INSERM U211), Nantes, France.
Cassard
A
A
Tesson
L
L
Le Mauff
B
B
Blanchard
D
D
Lublin
D
D
Soulillou
J P
JP
Anegon
I
I
D000818:Animals; D015703:Antigens, CD / Q000032:analysis / Q000096:biosynthesis* / Q000502:physiology; D001011:Aorta; D018958:CD55 Antigens; D018957:CD59 Antigens; D002470:Cell Survival / Q000187:drug effects / Q000502:physiology; D003169:Complement Inactivator Proteins / Q000096:biosynthesis* / Q000502:physiology; D003165:Complement System Proteins / Q000494:pharmacology*; D004730:Endothelium, Vascular / Q000166:cytology / Q000187:drug effects / Q000378:metabolism*; D005434:Flow Cytometry; D006801:Humans; D008562:Membrane Glycoproteins / Q000032:analysis / Q000096:biosynthesis* / Q000502:physiology; D051381:Rats; D017207:Rats, Sprague-Dawley; D011994:Recombinant Proteins / Q000032:analysis / Q000096:biosynthesis / Q000378:metabolism; D014162:Transfection
D015703:Antigens, CD; D018958:CD55 Antigens; D018957:CD59 Antigens; D003169:Complement Inactivator Proteins; D008562:Membrane Glycoproteins; D011994:Recombinant Proteins; D003165:Complement System Proteins